By Colin Kellaher
Optinose shares took flight in premarket trading Thursday after the pharmaceutical company agreed to be acquired by privately held Paratek Pharmaceuticals in a deal worth up to $330 million.
Paratek late Wednesday said it will pay an initial $9 a share in cash for Optinose, a 50% premium to Wednesday's closing price of $6 for the Yardley, Pa., company.
Optinose shareholders also will receive contingent value rights worth up to $5 a share tied to future sales of the chronic rhinosinusitis treatment Xhance, bringing the total potential deal value to $14 a share.
Optinose shares were recently up 59% to $9.56 in premarket trading.
The deal is slated to close as early as mid-2025.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 20, 2025 05:59 ET (09:59 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.